BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17531482)

  • 1. Design and synthesis of 3,3-piperidine hydroxamate analogs as selective TACE inhibitors.
    Lombart HG; Feyfant E; Joseph-McCarthy D; Huang A; Lovering F; Sun L; Zhu Y; Zeng C; Zhang Y; Levin J
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4333-7. PubMed ID: 17531482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion of potent MMP inhibitors into selective TACE inhibitors.
    Cherney RJ; King BW; Gilmore JL; Liu RQ; Covington MB; Duan JJ; Decicco CP
    Bioorg Med Chem Lett; 2006 Feb; 16(4):1028-31. PubMed ID: 16289878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and activity of quinolinylmethyl P1' alpha-sulfone piperidine hydroxamate inhibitors of TACE.
    Zhang C; Lovering F; Behnke M; Zask A; Sandanayaka V; Sun L; Zhu Y; Xu W; Zhang Y; Levin JI
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3445-8. PubMed ID: 19464885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.
    Park K; Aplasca A; Du MT; Sun L; Zhu Y; Zhang Y; Levin JI
    Bioorg Med Chem Lett; 2006 Aug; 16(15):3927-31. PubMed ID: 16723229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
    Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
    Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).
    Ott GR; Asakawa N; Lu Z; Liu RQ; Covington MB; Vaddi K; Qian M; Newton RC; Christ DD; Traskos JM; Decicco CP; Duan JJ
    Bioorg Med Chem Lett; 2008 Jan; 18(2):694-9. PubMed ID: 18061445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel thiol-based TACE inhibitors: rational design, synthesis, and SAR of thiol-containing aryl sulfonamides.
    Govinda Rao B; Bandarage UK; Wang T; Come JH; Perola E; Wei Y; Tian SK; Saunders JO
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2250-3. PubMed ID: 17289381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.
    Cherney RJ; Duan JJ; Voss ME; Chen L; Wang L; Meyer DT; Wasserman ZR; Hardman KD; Liu RQ; Covington MB; Qian M; Mandlekar S; Christ DD; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
    J Med Chem; 2003 May; 46(10):1811-23. PubMed ID: 12723945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulfonate ester hydroxamic acids as potent and selective inhibitors of TACE enzyme.
    Levin JI; Du MT
    Drug Des Discov; 2003; 18(4):123-6. PubMed ID: 15553924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, preliminary biological evaluation and molecular modeling of some new heterocyclic inhibitors of TACE.
    Sengupta P; Puri CS; Chokshi HA; Sheth CK; Midha AS; Chitturi TR; Thennati R; Murumkar PR; Yadav MR
    Eur J Med Chem; 2011 Nov; 46(11):5549-55. PubMed ID: 21963348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.
    Chen XT; Ghavimi B; Corbett RL; Xue CB; Liu RQ; Covington MB; Qian M; Vaddi KG; Christ DD; Hartman KD; Ribadeneira MD; Trzaskos JM; Newton RC; Decicco CP; Duan JJ
    Bioorg Med Chem Lett; 2007 Apr; 17(7):1865-70. PubMed ID: 17276676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors: Part I--discovery of two binding modes.
    Zhu Z; Mazzola R; Sinning L; McKittrick B; Niu X; Lundell D; Sun J; Orth P; Guo Z; Madison V; Ingram R; Beyer BM
    J Med Chem; 2008 Feb; 51(4):725-36. PubMed ID: 18247549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
    Sheppeck JE; Gilmore JL; Tebben A; Xue CB; Liu RQ; Decicco CP; Duan JJ
    Bioorg Med Chem Lett; 2007 May; 17(10):2769-74. PubMed ID: 17368021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.
    Levin JI; Chen JM; Cheung K; Cole D; Crago C; Santos ED; Du X; Khafizova G; MacEwan G; Niu C; Salaski EJ; Zask A; Cummons T; Sung A; Xu J; Zhang Y; Xu W; Ayral-Kaloustian S; Jin G; Cowling R; Barone D; Mohler KM; Black RA; Skotnicki JS
    Bioorg Med Chem Lett; 2003 Aug; 13(16):2799-803. PubMed ID: 12873518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.
    Zask A; Gu Y; Albright JD; Du X; Hogan M; Levin JI; Chen JM; Killar LM; Sung A; DiJoseph JF; Sharr MA; Roth CE; Skala S; Jin G; Cowling R; Mohler KM; Barone D; Black R; March C; Skotnicki JS
    Bioorg Med Chem Lett; 2003 Apr; 13(8):1487-90. PubMed ID: 12668018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1' groups.
    Chen JM; Jin G; Sung A; Levin JI
    Bioorg Med Chem Lett; 2002 Apr; 12(8):1195-8. PubMed ID: 11934587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reverse hydroxamate-based selective TACE inhibitors.
    Kamei N; Tanaka T; Kawai K; Miyawaki K; Okuyama A; Murakami Y; Arakawa Y; Haino M; Harada T; Shimano M
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2897-900. PubMed ID: 15125955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates.
    Levin JI; Chen JM; Laakso LM; Du M; Schmid J; Xu W; Cummons T; Xu J; Jin G; Barone D; Skotnicki JS
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1605-9. PubMed ID: 16426848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based rational design of peptide hydroxamic acid inhibitors to target tumor necrosis factor-α converting enzyme as potential therapeutics for hepatitis.
    Wu D; Gu Q; Zhao N; Xia F; Li Z
    J Drug Target; 2015 Dec; 23(10):936-42. PubMed ID: 26061299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-alpha converting enzyme.
    Holms J; Mast K; Marcotte P; Elmore I; Li J; Pease L; Glaser K; Morgan D; Michaelides M; Davidsen S
    Bioorg Med Chem Lett; 2001 Nov; 11(22):2907-10. PubMed ID: 11677124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.